Evaluation of Plaque Stability of Advanced Atherosclerotic Lesions in Apo E-Deficient Mice after Treatment with the Oral Factor Xa Inhibitor Rivaroxaban

Table 1

Weight, rivaroxaban plasma concentrations, and lipids levels.

	Control	Low	High	𝑃
Weight (g)	30.5 ± 3.4	29.4 ± 4.1	27.3 ± 3.5	^∗𝑃<.01
Rivaroxaban concentration (ng/mL)	<2.0	6.5 ± 1.5	24.2 ± 9.3	^∗𝑃<.01
Total cholesterol (mg/dL)	208.6 ± 68.0	218.8 ± 67.1	231.9 ± 55.0	ns
LDL cholesterol (mg/dL)	194.6 ± 68.5	203.4 ± 63.2	219.0 ± 51.9	ns
HDL cholesterol (mg/dL)	6.0 ± 2.1	4.9 ± 2.6	5.4 ± 2.9	ns
Triglycerides (mg/dL)	40.0 ± 16.8	52.0 ± 15.0	36.7 ± 12.0	ns

*high concentration versus control group.